Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

Aberrant activation of the JAK3-STAT signaling pathway is a characteristic feature of many hematological malignancies. In particular, hyperactivity of this cascade has been observed in natural killer/T-cell lymphoma (NKTL) cases. Although the first-in-class JAK3 inhibitor tofacitinib blocks JAK3 act...

Descripción completa

Detalles Bibliográficos
Autores principales: Nairismägi, M. -L., Gerritsen, M. E., Li, Z. M., Wijaya, G. C., Chia, B. K. H., Laurensia, Y., Lim, J. Q., Yeoh, K. W., Yao, X. S., Pang, W. L., Bisconte, A., Hill, R. J., Bradshaw, J. M., Huang, D., Song, T. L. L., Ng, C. C. Y., Rajasegaran, V., Tang, T., Tang, Q. Q., Xia, X. J., Kang, T. B., Teh, B. T., Lim, S. T., Ong, C. K., Tan, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940653/
https://www.ncbi.nlm.nih.gov/pubmed/29434279
http://dx.doi.org/10.1038/s41375-017-0004-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940653/
https://www.ncbi.nlm.nih.gov/pubmed/29434279
http://dx.doi.org/10.1038/s41375-017-0004-x

Ejemplares similares